BioLargo Reports Annual 2025 Operating and Financial Results

A Year of Disciplined Execution as BioLargo Gained Commercialization for Several Business Segments with $3.9 Million Cash Balance at Year End

WESTMINSTER, CALIFORNIA / ACCESS Newswire / March 5, 2026 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, today announced that its Annual Report for the year ended December 31, 2025. To view the filing in its entirety, please see: https://www.biolargo.com/sec-filings

BioLargo, Inc. President and CEO Dennis P. Calvert, commented, "2025 was a year of great accomplishment and great adversity, where, on the one hand, we managed through the termination of our largest customer's license and that loss of revenue, and, on the other, grew our engineering services revenue by 98%, and advanced our other business projects and divisions. We did what we said we would do, making significant commercial advancements in several business segments, setting the stage for revenues in new areas in 2026."

Calvert, concluded, "These accomplishments produced increased enterprise valuations in our Clyra Medical Technologies and Cellinity Battery divisions, both of which raised capital in 2025. Our Company remains very healthy with $3.9 million cash balance and varying shots on goal across several industries. We are as optimistic as ever with our emerging solutions surrounding surgical and wound care products, water treatment for the global PFAS contamination crisis and battery energy storage technology. We look forward to continuing our commercialization efforts and ramp in 2026."

2025 and Subsequent 2026 Highlights:

• BioLargo Subsidiary BEST Featured in Chemical Engineering Magazine for PFAS Breakthrough

  • https://www.biolargo.com/post/biolargo-subsidiary-best-featured-in-che ...

• BioLargo Subsidiary Clyra Medical Highlights Key Opinion Leader Presentation of Exceptional ViaCLYR(TM) Clinical Results at Leading Wound Care Symposium

  • https://www.biolargo.com/post/biolargo-subsidiary-clyra-medical-highli ...

• BioLargo Subsidiary Clyra Medical Technologies Secures First Stocking Order with Advanced Solution for ViaCLYR(TM) Wound Irrigation Solution

  • https://www.biolargo.com/post/biolargo-subsidiary-clyra-medical-techno ...